New pharmacologic agents for diabetes.

被引：8

作者：

Bailey C.J. ^{[1
]}

机构：

[1] Department of Pharmaceutical Sciences, Aston University, Aston Triangle

来源：

Current Diabetes Reports | 2001年 / 1卷 / 2期

关键词：

Troglitazone; Lipoic Acid; Sibutramine; Hepatic Glucose Output; Improve Insulin Action;

D O I：

10.1007/s11892-001-0023-9

中图分类号：

学科分类号：

摘要：

New agents are being developed to address the underlying endocrinopathies and metabolic disturbances of type 2 diabetes. Stimulants of the nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma) are being identified to selectively improve insulin actions, and dual agonists of PPAR gamma and PPAR alpha are being evaluated for enhanced control of hyperglycemia and dyslipidemia. Novel activators of insulin receptor phosphorylation and inhibitors of receptor dephosphorylation are offering encouraging leads for new agents. Analogues of glucagon-like peptide-1 that increase glucose-induced insulin secretion may additionally increase beta-cell neogenesis from progenitor duct cells. The amylin analogue pramlintide, which suppresses glucagon secretion and reduces weight, is advancing in clinical trial. Direct stimulants of glucose utilization and partial inhibitors of gluconeogenesis are providing useful new drug templates. Thus, new pharmacologic approaches are emerging to treat the multiple lesions of type 2 diabetes.

引用

页码：119 / 126

页数：7

共 202 条

[1]

Turner RC(1999)Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus JAMA 281 2005-2012

[2]

Cull CA(1997)Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes Diabetes Rev 5 177-269

[3]

Frighi V(1999)Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria Lancet 354 617-621

[4]

Holman RR(1999)New pharmacological approaches to glycemic control Diabetes Rev 7 94-113

[5]

DeFronzo RA(2000)Potential new treatments for type 2 diabetes Trends Pharmacol Sci 21 259-265

[6]

Bailey CJ(2001)New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers Annu Rev Med 52 239-257

[7]

Bailey CJ(1999), the ultimate thrifty gene Diabetologia 42 1033-1049

[8]

Mudaliar S(1999)Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr Rev 20 649-688

[9]

Henry RR(1999)Thiazolidinediones: a new class of antidiabetic drugs Diabetic Med 16 179-192

[10]

Auwerx J(2001)The hormone resistin links obesity to diabetes Nature 409 307-312

← 1 2 3 4 5 6 7 8 9 10 →